Aerie Pharmaceuticals Inc (NASDAQ:AERI) Short Interest Update

Share on StockTwits

Aerie Pharmaceuticals Inc (NASDAQ:AERI) saw a significant decline in short interest during the month of July. As of July 31st, there was short interest totalling 8,050,000 shares, a decline of 10.6% from the July 15th total of 9,000,000 shares. Based on an average trading volume of 879,200 shares, the days-to-cover ratio is currently 9.2 days. Approximately 18.4% of the company’s shares are sold short.

Several equities research analysts have recently issued reports on the company. SunTrust Banks lowered their price objective on Aerie Pharmaceuticals from $26.00 to $22.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Needham & Company LLC reduced their price objective on shares of Aerie Pharmaceuticals from $32.00 to $26.00 and set a “buy” rating on the stock in a research report on Friday. Piper Sandler reduced their price target on Aerie Pharmaceuticals from $35.00 to $25.00 in a report on Friday. Mizuho boosted their price objective on Aerie Pharmaceuticals from $27.00 to $29.00 and gave the company a “buy” rating in a report on Friday. Finally, BidaskClub downgraded Aerie Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, July 7th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $31.50.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Endurance Wealth Management Inc. boosted its holdings in shares of Aerie Pharmaceuticals by 32.6% in the 1st quarter. Endurance Wealth Management Inc. now owns 3,050 shares of the company’s stock valued at $41,000 after buying an additional 750 shares in the last quarter. First Mercantile Trust Co. grew its holdings in Aerie Pharmaceuticals by 17.7% in the first quarter. First Mercantile Trust Co. now owns 8,124 shares of the company’s stock worth $110,000 after purchasing an additional 1,222 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Aerie Pharmaceuticals by 60.0% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,601 shares of the company’s stock worth $49,000 after purchasing an additional 1,351 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Aerie Pharmaceuticals by 39.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,030 shares of the company’s stock valued at $74,000 after purchasing an additional 1,429 shares during the last quarter. Finally, Swiss National Bank boosted its position in shares of Aerie Pharmaceuticals by 2.0% in the 1st quarter. Swiss National Bank now owns 85,200 shares of the company’s stock worth $1,150,000 after purchasing an additional 1,700 shares in the last quarter.

NASDAQ AERI opened at $12.61 on Friday. Aerie Pharmaceuticals has a one year low of $10.80 and a one year high of $26.26. The company has a debt-to-equity ratio of 1.61, a quick ratio of 4.02 and a current ratio of 4.28. The company has a market capitalization of $583.43 million, a price-to-earnings ratio of -2.86 and a beta of 0.94. The company’s 50-day simple moving average is $13.57 and its two-hundred day simple moving average is $15.60.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.79) by ($0.04). Aerie Pharmaceuticals had a negative net margin of 252.92% and a negative return on equity of 95.74%. Equities analysts expect that Aerie Pharmaceuticals will post -3.52 earnings per share for the current fiscal year.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Read More: Percentage Gainers

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Hermes Pacific Investments  Stock Price Up 8.3%
Hermes Pacific Investments Stock Price Up 8.3%
Fincera  Trading Down 96.9%
Fincera Trading Down 96.9%
Western Energy Services   Shares Down 0.2%
Western Energy Services Shares Down 0.2%
Petroteq Energy  Trading Up 21.4%
Petroteq Energy Trading Up 21.4%
Yosen Group  Stock Price Up 52.7%
Yosen Group Stock Price Up 52.7%
Whiting USA Trust II  Trading Up 23.8%
Whiting USA Trust II Trading Up 23.8%


© 2006-2020 Ticker Report